CoChat

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death

Open access

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Abstract

The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. The compound APR‐246 (PRIMA‐1Met/Eprenetapopt) is converted to methylene quinuclidinone (MQ) that targets mutant p53 protein and perturbs cellular antioxidant balance. APR‐246 is currently tested in a phase III clinical trial in myelodysplastic syndrome (MDS). By in vitro , ex vivo, and in vivo models, we show that combined treatment with APR‐246 and inhibitors of efflux pump MRP1/ABCC1 results in synergistic tumor cell death, which is more pronounced in TP53 mutant cells. This is associated with altered cellular thiol status and increased intracellular glutathione‐conjugated MQ (GS‐MQ). Due to the reversibility of MQ conjugation, GS‐MQ forms an intracellular drug reservoir that increases availability of MQ for targeting mutant p53. Our study shows that redox homeostasis is a critical determinant of the response to mutant p53‐targeted cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201910852

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure EV1 Multidrug resistance‐associated protein 1 (MRP1) inhibition synergizes with APR‐246 Box‐and‐whisker plot of Pearson correlations between PRIMA‐1 area‐under‐the‐curve (AUC) and 18,827 transcripts from the DepMap portal in 37 ovarian cancer cell lines, central band indicates median, boxes indicate 25th and 75th percentile, and whiskers show 1st and 99th percentile outlier genes. High ABCC1 (MRP1) is labeled and correlates with low PRIMA‐1 sensitivity.Growth suppression after APR‐246 treatment +/− MK‐571 for 72 h according to the resazurin assay in esophageal cancer cell lines (n = 3). See Appendix Table S1 for more detailed information. Data are represented as mean ± SEM.
Figure EV1 Multidrug resistance‐associated protein 1 (MRP1) inhibition synergizes with APR‐246 Box‐and‐whisker plot of Pearson correlations between PRIMA‐1 area‐under‐the‐curve (AUC) and 18,827 transcripts from the DepMap portal in 37 ovarian cancer cell lines, central band indicates median, boxes indicate 25th and 75th percentile, and whiskers show 1st and 99th percentile outlier genes. High ABCC1 (MRP1) is labeled and correlates with low PRIMA‐1 sensitivity.Growth suppression after APR‐246 treatment +/− MK‐571 for 72 h according to the resazurin assay in esophageal cancer cell lines (n = 3). See Appendix Table S1 for more detailed information. Data are represented as mean ± SEM.CC BY · PubMed Central
Figure 1 Inhibition of efflux pump MRP1 synergizes with APR‐246 Growth suppression in cancer cells after 72 h of treatment with APR‐246 +/− MRP1 inhibitor MK‐571 as shown by the WST‐1 assay (n ≥ 3, n shown in Appendix Table S1). Cross in heatmap indicates no data available.Growth suppression in human dermal fibroblasts (HDF) by WST‐1 assay after 72 h with APR‐246 +/− MK‐571 (n = 3).Mean IC50 values (µM) for APR‐246 +/− 20 μM MK‐571 of 21 cell lines. *P < 0.0001, Wilcoxon test. Each dot represents one cell line. Mean IC50 values and n shown in Appendix Table S1.ZIP synergy scores of most synergistic area sub‐grouped according to TP53 gene status for 21 cell lines. Each dot represents one cell line. Scores and n are shown in Appendix Table S1.Sub‐G1 DNA content of OVCAR‐3 cells (R248Q) after APR‐246 +/− MK‐571 treatment as assessed by propidium iodide staining at 48 h (n = 3).OVCAR‐3 cell confluency by IncuCyte® during 72 h of treatment with APR‐246 +/− MK‐571 (n = 3).Growth suppression in HCT116 WT (n = 4) and R248W cells (n = 3) after 72‐h treatment with APR‐246 +/− MRP1 inhibitor Reversan, as shown by WST‐1.Western blot analysis of MRP1 (Cell Signaling), p53 (DO‐1), and GAPDH of HCT116 WT and R248W cells 48 h after transfection with negative control siRNAs or siRNAs targeting MRP1 or p53.Growth suppression (WST‐1 assay) of HCT116 WT and R248W cells transfected with MRP1 siRNA (n ≥ 5 and n ≥ 2, respectively) after 48 h APR‐246 treatment. Indicated values are average of four individual siRNAs targeting MRP1 and two individual negative control siRNAs. Data and n of individual siRNAs are shown in Appendix Fig S1J; data are also part of Fig 7B.Western blot analysis of MRP1 (Cell Signaling), p53 (DO‐1), and GAPDH of HCT116 WT and R248W cells 72 h after transfection with empty vector (EV) and MRP1 expression vector.Growth suppression (WST‐1 assay) of HCT116 WT and R248W cells transfected with empty vector (EV) and MRP1 expression vector after 72 h APR‐246 treatment (n = 4). Data are also part of Appendix Fig S7E. Data information: TP53 status is shown for each cell line. Data are represented as mean ± SEM. See also Fig EV1, Appendix Fig S1 and Appendix Table S1. Source data are available online for this figure.
Figure 1 Inhibition of efflux pump MRP1 synergizes with APR‐246 Growth suppression in cancer cells after 72 h of treatment with APR‐246 +/− MRP1 inhibitor MK‐571 as shown by the WST‐1 assay (n ≥ 3, n shown in Appendix Table S1). Cross in heatmap indicates no data available.Growth suppression in human dermal fibroblasts (HDF) by WST‐1 assay after 72 h with APR‐246 +/− MK‐571 (n = 3).Mean IC50 values (µM) for APR‐246 +/− 20 μM MK‐571 of 21 cell lines. *P < 0.0001, Wilcoxon test. Each dot represents one cell line. Mean IC50 values and n shown in Appendix Table S1.ZIP synergy scores of most synergistic area sub‐grouped according to TP53 gene status for 21 cell lines. Each dot represents one cell line. Scores and n are shown in Appendix Table S1.Sub‐G1 DNA content of OVCAR‐3 cells (R248Q) after APR‐246 +/− MK‐571 treatment as assessed by propidium iodide staining at 48 h (n = 3).OVCAR‐3 cell confluency by IncuCyte® during 72 h of treatment with APR‐246 +/− MK‐571 (n = 3).Growth suppression in HCT116 WT (n = 4) and R248W cells (n = 3) after 72‐h treatment with APR‐246 +/− MRP1 inhibitor Reversan, as shown by WST‐1.Western blot analysis of MRP1 (Cell Signaling), p53 (DO‐1), and GAPDH of HCT116 WT and R248W cells 48 h after transfection with negative control siRNAs or siRNAs targeting MRP1 or p53.Growth suppression (WST‐1 assay) of HCT116 WT and R248W cells transfected with MRP1 siRNA (n ≥ 5 and n ≥ 2, respectively) after 48 h APR‐246 treatment. Indicated values are average of four individual siRNAs targeting MRP1 and two individual negative control siRNAs. Data and n of individual siRNAs are shown in Appendix Fig S1J; data are also part of Fig 7B.Western blot analysis of MRP1 (Cell Signaling), p53 (DO‐1), and GAPDH of HCT116 WT and R248W cells 72 h after transfection with empty vector (EV) and MRP1 expression vector.Growth suppression (WST‐1 assay) of HCT116 WT and R248W cells transfected with empty vector (EV) and MRP1 expression vector after 72 h APR‐246 treatment (n = 4). Data are also part of Appendix Fig S7E. Data information: TP53 status is shown for each cell line. Data are represented as mean ± SEM. See also Fig EV1, Appendix Fig S1 and Appendix Table S1. Source data are available online for this figure.CC BY · PubMed Central
Figure 2 MK‐571 enhances the anti‐tumor activity of APR‐246 in vivo and ex vivo Growth of Eso26 xenografts (R248W mutant TP53) in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. P values determined by one‐way ANOVA with Tukey’s correction at day 18, n is indicated in the figure.Kaplan–Meier plot of time to reach 1,400 mm3 tumor volume in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. Mice that were culled at ethical endpoints prior to reaching a tumor volume of > 1,400 mm3 are marked as censored observations. P values were determined by Log‐rank (Mantel–Cox) test between different treatment groups. n is indicated in the figure.Quantification of Ki67 immunohistochemistry staining of Eso26 xenograft tumors at an early timepoint (5 days) or post‐treatment/late timepoint (> 22 days) after treatment initiation with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg). Dots indicate individual tumors.Quantification of cleaved caspase 3 immunohistochemistry staining of Eso26 xenograft tumors in same tumors as shown in Fig 2C. Dots indicate individual tumors.Representative images of hematoxylin/eosin (H&E) staining and immunostaining of Ki67, cleaved caspase 3 and p53, post‐treatment/late timepoint (> 22 days after treatment initiation) with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg).Growth suppression determined by the ATP‐based CTG assay in colorectal cancer patient‐derived organoids (colo‐PDO) after treatment with APR‐246 +/− MK‐571 (n = 3).IC50 values (µM) APR‐246 +/− 20 μM MK‐571 in indicated PDOs (colo‐PDO or esophageal adenocarcinoma patient‐derived PDO [eso‐PDO]). *P = 0.04, paired t‐test (n = 3 except colo‐PDO2 and eso‐PDO3 where n = 2).Organoid area (in black, left y‐axis) and PI intensity (in red, right y‐axis) of colo‐PDO1 and colo‐PDO2 as determined by image analysis 72 h after treatment with APR‐246 +/− MK‐571 (n = 3).Highest synergy score according to the ZIP model based on growth suppression as shown by CTG assay (ATP‐based) or image analysis (Area and PI) in eso‐PDOs and colo‐PDOs. Scores are shown on a log scale. Score above 0 indicates synergy. Each dot indicates one individual experiment. Data information: TP53 status is indicated. Data are represented as mean ± SEM. See also Fig EV2, Appendix Fig S2 and Appendix Table S2.
Figure 2 MK‐571 enhances the anti‐tumor activity of APR‐246 in vivo and ex vivo Growth of Eso26 xenografts (R248W mutant TP53) in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. P values determined by one‐way ANOVA with Tukey’s correction at day 18, n is indicated in the figure.Kaplan–Meier plot of time to reach 1,400 mm3 tumor volume in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. Mice that were culled at ethical endpoints prior to reaching a tumor volume of > 1,400 mm3 are marked as censored observations. P values were determined by Log‐rank (Mantel–Cox) test between different treatment groups. n is indicated in the figure.Quantification of Ki67 immunohistochemistry staining of Eso26 xenograft tumors at an early timepoint (5 days) or post‐treatment/late timepoint (> 22 days) after treatment initiation with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg). Dots indicate individual tumors.Quantification of cleaved caspase 3 immunohistochemistry staining of Eso26 xenograft tumors in same tumors as shown in Fig 2C. Dots indicate individual tumors.Representative images of hematoxylin/eosin (H&E) staining and immunostaining of Ki67, cleaved caspase 3 and p53, post‐treatment/late timepoint (> 22 days after treatment initiation) with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg).Growth suppression determined by the ATP‐based CTG assay in colorectal cancer patient‐derived organoids (colo‐PDO) after treatment with APR‐246 +/− MK‐571 (n = 3).IC50 values (µM) APR‐246 +/− 20 μM MK‐571 in indicated PDOs (colo‐PDO or esophageal adenocarcinoma patient‐derived PDO [eso‐PDO]). *P = 0.04, paired t‐test (n = 3 except colo‐PDO2 and eso‐PDO3 where n = 2).Organoid area (in black, left y‐axis) and PI intensity (in red, right y‐axis) of colo‐PDO1 and colo‐PDO2 as determined by image analysis 72 h after treatment with APR‐246 +/− MK‐571 (n = 3).Highest synergy score according to the ZIP model based on growth suppression as shown by CTG assay (ATP‐based) or image analysis (Area and PI) in eso‐PDOs and colo‐PDOs. Scores are shown on a log scale. Score above 0 indicates synergy. Each dot indicates one individual experiment. Data information: TP53 status is indicated. Data are represented as mean ± SEM. See also Fig EV2, Appendix Fig S2 and Appendix Table S2.CC BY · PubMed Central
Figure EV2 MRP1 inhibition potentiates anti‐tumoral activity of APR‐246 in vivo and ex vivo Representative bright‐field and PI/Hoechst staining images of colo‐PDO1 after 72‐h treatment with APR‐246 +/− MK‐571.Representative bright‐field and PI/Hoechst staining images of colo‐PDO2 after 72‐h treatment with APR‐246 +/− MK‐571. Data information: TP53 status is indicated. See Appendix Table S2 for extended information. Source data are available online for this figure.
Figure EV2 MRP1 inhibition potentiates anti‐tumoral activity of APR‐246 in vivo and ex vivo Representative bright‐field and PI/Hoechst staining images of colo‐PDO1 after 72‐h treatment with APR‐246 +/− MK‐571.Representative bright‐field and PI/Hoechst staining images of colo‐PDO2 after 72‐h treatment with APR‐246 +/− MK‐571. Data information: TP53 status is indicated. See Appendix Table S2 for extended information. Source data are available online for this figure.CC BY · PubMed Central
Figure 3 Inhibition of MRP1 efflux pump activity increases 14C‐APR‐246/MQ accumulation in cancer cells Chemical structure of 14C ‐APR‐246 and its active product MQ. 14C accumulation (cpm/mg/ml) in 11 cell lines after 24 h 14C ‐APR‐246 +/− MK‐571 treatment (n ≥ 3). *P = 0.0006, paired t‐test. 14C‐accumulation and n of individual cell lines as shown in Appendix Table S3. 14C accumulation (cpm/mg/ml) in HCT116 (WT and R248W) cells after 24 h + treatment with 14C ‐APR‐246 +/− MK‐571 or Reversan (n ≥ 3, each dot indicates one individual experiment). 14C accumulation (cpm/mg/ml) in HCT116 WT and R248W cells (n ≥ 3 and ≥ 2) transfected with MRP1 siRNAs after 24 h of 14C‐APR‐246 treatment. Indicated values represent four individual MRP1 siRNAs and two individual negative control (Ctrl) siRNAs, where each dot is an individual siRNA. Mean of 14C‐accumulation after treatment and n with individual siRNA sequences is shown in Appendix Table S4. *P = 0.04 and for R248W P = 0.06, Wilcoxon matched‐pairs signed rank test. Data information: TP53 status has been indicated. Data are represented as mean ± SEM. See also Fig EV3, Appendix Fig S3 and Appendix Tables S3 and S4. Source data are available online for this figure.
Figure 3 Inhibition of MRP1 efflux pump activity increases 14C‐APR‐246/MQ accumulation in cancer cells Chemical structure of 14C ‐APR‐246 and its active product MQ. 14C accumulation (cpm/mg/ml) in 11 cell lines after 24 h 14C ‐APR‐246 +/− MK‐571 treatment (n ≥ 3). *P = 0.0006, paired t‐test. 14C‐accumulation and n of individual cell lines as shown in Appendix Table S3. 14C accumulation (cpm/mg/ml) in HCT116 (WT and R248W) cells after 24 h + treatment with 14C ‐APR‐246 +/− MK‐571 or Reversan (n ≥ 3, each dot indicates one individual experiment). 14C accumulation (cpm/mg/ml) in HCT116 WT and R248W cells (n ≥ 3 and ≥ 2) transfected with MRP1 siRNAs after 24 h of 14C‐APR‐246 treatment. Indicated values represent four individual MRP1 siRNAs and two individual negative control (Ctrl) siRNAs, where each dot is an individual siRNA. Mean of 14C‐accumulation after treatment and n with individual siRNA sequences is shown in Appendix Table S4. *P = 0.04 and for R248W P = 0.06, Wilcoxon matched‐pairs signed rank test. Data information: TP53 status has been indicated. Data are represented as mean ± SEM. See also Fig EV3, Appendix Fig S3 and Appendix Tables S3 and S4. Source data are available online for this figure.CC BY · PubMed Central
Figure EV3 Inhibition of MRP1 efflux pump activity increases 14C‐APR‐246/MQ accumulation in cancer cells 14C accumulation (cpm/mg/ml) in 11 cancer cell lines after 24‐h treatment with 10 or 25 μM 14C ‐APR‐246 +/− MK‐571 (n ≥ 3). Detailed information including n is shown in Appendix Table S3. Data are represented as mean ± SEM.
Figure EV3 Inhibition of MRP1 efflux pump activity increases 14C‐APR‐246/MQ accumulation in cancer cells 14C accumulation (cpm/mg/ml) in 11 cancer cell lines after 24‐h treatment with 10 or 25 μM 14C ‐APR‐246 +/− MK‐571 (n ≥ 3). Detailed information including n is shown in Appendix Table S3. Data are represented as mean ± SEM.CC BY · PubMed Central
Figure 4 MRP1 inhibition increases GS‐MQ content, forming a reservoir of MQ for interaction with other targets APR‐246 content in OVCAR‐3 cells (TP53 R248Q) 24 h after treatment with APR‐246 +/− MK‐571 (n = 3).Glutathione‐conjugated MQ (GS‐MQ) in OVCAR‐3 cells after 24‐h treatment with APR‐246 +/− MK‐571 (n = 2).Amount of GS‐MQ at indicated timepoints after incubation of GS‐MQ +/− NAC (n = 2). See Fig EV4 for chemical reaction.Amount of GS‐MQ by LC‐MS (green line, left axis) and NAC‐MQ (purple line, right axis) over time after incubation of GS‐MQ with NAC (n = 2). Values on y‐axes are not comparable because GS‐MQ and NAC‐MQ have different response signals on MS. Data information: Indicated values are assessed by LC‐MS. Data are represented as mean ± SEM. See also Appendix Fig S4.
Figure 4 MRP1 inhibition increases GS‐MQ content, forming a reservoir of MQ for interaction with other targets APR‐246 content in OVCAR‐3 cells (TP53 R248Q) 24 h after treatment with APR‐246 +/− MK‐571 (n = 3).Glutathione‐conjugated MQ (GS‐MQ) in OVCAR‐3 cells after 24‐h treatment with APR‐246 +/− MK‐571 (n = 2).Amount of GS‐MQ at indicated timepoints after incubation of GS‐MQ +/− NAC (n = 2). See Fig EV4 for chemical reaction.Amount of GS‐MQ by LC‐MS (green line, left axis) and NAC‐MQ (purple line, right axis) over time after incubation of GS‐MQ with NAC (n = 2). Values on y‐axes are not comparable because GS‐MQ and NAC‐MQ have different response signals on MS. Data information: Indicated values are assessed by LC‐MS. Data are represented as mean ± SEM. See also Appendix Fig S4.CC BY · PubMed Central
Figure EV4 MQ adduct formation is reversible. Chemical reaction scheme for the formation of NAC‐MQ upon addition of NAC to GSH‐MQ conjugates. Yellow indicates reactive thiol.
Figure EV4 MQ adduct formation is reversible. Chemical reaction scheme for the formation of NAC‐MQ upon addition of NAC to GSH‐MQ conjugates. Yellow indicates reactive thiol.CC BY · PubMed Central
Figure 5 APR‐246 sensitivity is dependent on the presence of mutant p53, cellular thiol status and drug accumulation Mean IC50 (µM) values of APR‐246 in 17 different cell lines (n ≥ 3) as shown by WST‐1. *P = 0.03, Mann–Whitney test. Mean IC50 (µM) values for APR‐246 treatment are also shown in Fig 1C. Values and n are listed in Appendix Table S1.Box‐and‐whisker plot of Pearson correlations between PRIMA‐1 area‐under‐the‐curve (AUC) and the levels of 225 different metabolites from the DepMap portal. Central band indicates median, boxes indicate 25th and 75th percentile, and whiskers show 2.5th and 97.5th percentile outlier metabolites. High GSH and GSSG (in red) correlate with low PRIMA‐1 sensitivity.Total intracellular glutathione (GSH + GSSG) as shown by glutathione reductase (GR) re‐cycling assay in H1299 R175H (tet‐off) (+/− doxycycline) and H1299 −/− cells 24 h after seeding (n = 3). Indicated values are fold change compared with mutant TP53 cells.Total intracellular glutathione (GSH + GSSG) as shown by GR re‐cycling assay in untreated HCT116 (R248W, WT, and −/−) cells 48 h after seeding (n = 3, 5, or 2, respectively). Indicated values are fold change to mutant TP53 cells. Part of this data is shown in Fig EV6.Thiol tracker staining by flow cytometry 48 h after seeding of the indicated untreated cells (n = 2).Correlation between 14C accumulation (cpm/mg/ml) after treatment with 25 µM 14C‐APR‐246 and IC50 (µM) values for APR‐246 in 11 cell lines (n ≥ 3) (r = −0.66, P = 0.03, Pearson correlation). Each dot represents one cell line, 14C accumulation data are shown in Fig 3B and values and n for individual cell lines are listed in Appendix Table S1 and S3. ABCC1 mRNA Expression, RSEM (Batch normalized from Illumina HiSeq_RNASeqV2) in lung cancer (luad & lusc studies, *P < 0.0001) and colon adenocarcinoma (coad study, *P = 0.005) grouped into having no alterations or putative driver missense mutations in TP53. Statistical analysis by Mann–Whitney test, n is indicated in the figure. 14C accumulation (cpm/mg/ml) in H1299 R175H cells (+/− doxycycline) and H1299 −/− cells after 24‐h treatment with 14C‐APR‐246 (n = 2).Growth suppression in H1299 R175H cells (+/− doxycycline) and H1299 −/− cells treated for 72 h with APR‐246 as shown by WST‐1 assay (n = 3). Data information: TP53 status is indicated for each cell line. Data are represented as mean ± SEM. See also Fig EV5 and Appendix Fig S5. Source data are available online for this figure.
Figure 5 APR‐246 sensitivity is dependent on the presence of mutant p53, cellular thiol status and drug accumulation Mean IC50 (µM) values of APR‐246 in 17 different cell lines (n ≥ 3) as shown by WST‐1. *P = 0.03, Mann–Whitney test. Mean IC50 (µM) values for APR‐246 treatment are also shown in Fig 1C. Values and n are listed in Appendix Table S1.Box‐and‐whisker plot of Pearson correlations between PRIMA‐1 area‐under‐the‐curve (AUC) and the levels of 225 different metabolites from the DepMap portal. Central band indicates median, boxes indicate 25th and 75th percentile, and whiskers show 2.5th and 97.5th percentile outlier metabolites. High GSH and GSSG (in red) correlate with low PRIMA‐1 sensitivity.Total intracellular glutathione (GSH + GSSG) as shown by glutathione reductase (GR) re‐cycling assay in H1299 R175H (tet‐off) (+/− doxycycline) and H1299 −/− cells 24 h after seeding (n = 3). Indicated values are fold change compared with mutant TP53 cells.Total intracellular glutathione (GSH + GSSG) as shown by GR re‐cycling assay in untreated HCT116 (R248W, WT, and −/−) cells 48 h after seeding (n = 3, 5, or 2, respectively). Indicated values are fold change to mutant TP53 cells. Part of this data is shown in Fig EV6.Thiol tracker staining by flow cytometry 48 h after seeding of the indicated untreated cells (n = 2).Correlation between 14C accumulation (cpm/mg/ml) after treatment with 25 µM 14C‐APR‐246 and IC50 (µM) values for APR‐246 in 11 cell lines (n ≥ 3) (r = −0.66, P = 0.03, Pearson correlation). Each dot represents one cell line, 14C accumulation data are shown in Fig 3B and values and n for individual cell lines are listed in Appendix Table S1 and S3. ABCC1 mRNA Expression, RSEM (Batch normalized from Illumina HiSeq_RNASeqV2) in lung cancer (luad & lusc studies, *P < 0.0001) and colon adenocarcinoma (coad study, *P = 0.005) grouped into having no alterations or putative driver missense mutations in TP53. Statistical analysis by Mann–Whitney test, n is indicated in the figure. 14C accumulation (cpm/mg/ml) in H1299 R175H cells (+/− doxycycline) and H1299 −/− cells after 24‐h treatment with 14C‐APR‐246 (n = 2).Growth suppression in H1299 R175H cells (+/− doxycycline) and H1299 −/− cells treated for 72 h with APR‐246 as shown by WST‐1 assay (n = 3). Data information: TP53 status is indicated for each cell line. Data are represented as mean ± SEM. See also Fig EV5 and Appendix Fig S5. Source data are available online for this figure.CC BY · PubMed Central
Figure EV5 APR‐246 sensitivity is dictated by the presence of mutant p53, cellular thiol status, and drug accumulation Growth suppression of isogenic H1299, Saos‐2 and HCT116 cells with different TP53 status after 72 h APR‐246 treatment, as assessed by the WST‐1 assay (n ≥ 3). The data is also shown in Fig 1A and Appendix Fig S1A, n in Appendix Table S1.Correlation of PRIMA‐1 AUC with GSH and GSSG abundance in 708 cell lines from the DepMap portal. R and P values were determined by Pearson’s correlation.Total GSH + GSSG by a GR re‐cycling assay in HCT116 WT and R248W cells 48 h after siRNA p53 transfection. Values are averages of 1‐2 different siRNAs against TP53 and 1‐2 different controls (WT n = 3 R248W n = 2), individual values are shown in Appendix Fig S7K. 14C‐accumulation (cpm/(mg/ml)) in HCT116 WT and R248W cells 24 h after treatment with 14C‐APR‐246 and 48 h after transfection of siRNAs against p53. Values are averages of 2 different siRNAs against p53 and 2 different controls (WT n = 3 R248W n = 2). Values of individual siRNAs are shown in Appendix Table S4.Growth suppression in HCT116 WT and R248W cells after 48 h of APR‐246 treatment and 96 h post‐transfection of +/− siRNAs targeting p53 as determined by the WST‐1 assay. Values are averages of 2 different siRNAs against TP53 and 2 different controls (WT n = 5–6 and R248W n = 3) *P = 0.047, Paired t‐test. Data information: TP53 status is indicated for each cell line. Data are represented as mean ± SEM.
Figure EV5 APR‐246 sensitivity is dictated by the presence of mutant p53, cellular thiol status, and drug accumulation Growth suppression of isogenic H1299, Saos‐2 and HCT116 cells with different TP53 status after 72 h APR‐246 treatment, as assessed by the WST‐1 assay (n ≥ 3). The data is also shown in Fig 1A and Appendix Fig S1A, n in Appendix Table S1.Correlation of PRIMA‐1 AUC with GSH and GSSG abundance in 708 cell lines from the DepMap portal. R and P values were determined by Pearson’s correlation.Total GSH + GSSG by a GR re‐cycling assay in HCT116 WT and R248W cells 48 h after siRNA p53 transfection. Values are averages of 1‐2 different siRNAs against TP53 and 1‐2 different controls (WT n = 3 R248W n = 2), individual values are shown in Appendix Fig S7K. 14C‐accumulation (cpm/(mg/ml)) in HCT116 WT and R248W cells 24 h after treatment with 14C‐APR‐246 and 48 h after transfection of siRNAs against p53. Values are averages of 2 different siRNAs against p53 and 2 different controls (WT n = 3 R248W n = 2). Values of individual siRNAs are shown in Appendix Table S4.Growth suppression in HCT116 WT and R248W cells after 48 h of APR‐246 treatment and 96 h post‐transfection of +/− siRNAs targeting p53 as determined by the WST‐1 assay. Values are averages of 2 different siRNAs against TP53 and 2 different controls (WT n = 5–6 and R248W n = 3) *P = 0.047, Paired t‐test. Data information: TP53 status is indicated for each cell line. Data are represented as mean ± SEM.CC BY · PubMed Central
Figure 6 MRP1 inhibitor MK‐571 shifts cellular thiol pools, further potentiating APR‐246 efficacy Total intracellular glutathione (GSH + GSSG per 106 cells), as determined by GR re‐cycling assay after 24‐h MK‐571 treatment in six different cell lines (n ≥ 3, except HCT116 WT n = 2). *P = 0.014, Paired t‐test. Each dot represents one cell line, see Fig EV6 for individual cell lines and n.Intracellular oxidized glutathione (GSSG per 106 cells) as shown by LC‐MS in OVCAR‐3 (R248Q TP53) cells at 24‐h treatment with APR‐246 +/− MK‐571 (n = 3).Intracellular reduced glutathione (GSH per 106 cells) as shown by LC‐MS in OVCAR‐3 cells at 24‐h treatment with APR‐246 +/− MK‐571 (n = 3).Western blot analysis of MRP1 (Cell Signaling), xCT, and GAPDH of OVCAR‐3 cells treated with APR‐246 +/− MK‐571 for 24 h.Western blot analysis of MRP1 (Cell Signaling), xCT, and GAPDH of HCT116 WT and R248W cells treated with APR‐246 +/− MK‐571 for 24 h.Intracellular cystine (CySS per 106 cells) as shown by LC‐MS in OVCAR‐3 cells at 24 h treatment with APR‐246 +/− MK‐571 (n = 3).Intracellular cysteine (Cys per 106 cells) as shown by LC‐MS in OVCAR‐3 cells at 24 h treatment with APR‐246 +/− MK‐571 (n = 3). Data information: TP53 status is indicated. Data are represented as mean ± SEM. See also Fig EV6 and Appendix Fig S6. Source data are available online for this figure.
Figure 6 MRP1 inhibitor MK‐571 shifts cellular thiol pools, further potentiating APR‐246 efficacy Total intracellular glutathione (GSH + GSSG per 106 cells), as determined by GR re‐cycling assay after 24‐h MK‐571 treatment in six different cell lines (n ≥ 3, except HCT116 WT n = 2). *P = 0.014, Paired t‐test. Each dot represents one cell line, see Fig EV6 for individual cell lines and n.Intracellular oxidized glutathione (GSSG per 106 cells) as shown by LC‐MS in OVCAR‐3 (R248Q TP53) cells at 24‐h treatment with APR‐246 +/− MK‐571 (n = 3).Intracellular reduced glutathione (GSH per 106 cells) as shown by LC‐MS in OVCAR‐3 cells at 24‐h treatment with APR‐246 +/− MK‐571 (n = 3).Western blot analysis of MRP1 (Cell Signaling), xCT, and GAPDH of OVCAR‐3 cells treated with APR‐246 +/− MK‐571 for 24 h.Western blot analysis of MRP1 (Cell Signaling), xCT, and GAPDH of HCT116 WT and R248W cells treated with APR‐246 +/− MK‐571 for 24 h.Intracellular cystine (CySS per 106 cells) as shown by LC‐MS in OVCAR‐3 cells at 24 h treatment with APR‐246 +/− MK‐571 (n = 3).Intracellular cysteine (Cys per 106 cells) as shown by LC‐MS in OVCAR‐3 cells at 24 h treatment with APR‐246 +/− MK‐571 (n = 3). Data information: TP53 status is indicated. Data are represented as mean ± SEM. See also Fig EV6 and Appendix Fig S6. Source data are available online for this figure.CC BY · PubMed Central
Figure EV6 MRP1 inhibitor MK‐571 shifts cellular thiol pools, further potentiating APR‐246 efficacy Total intracellular glutathione (GSH + GSSG) levels in six cell lines after 24‐h incubation +/− MK‐571 as determined by a glutathione reductase (GR) re‐cycling assay (n ≥ 3 for each cell line except HCT116 −/− where n = 2, n indicates individual experiments). Mean values for each cell line shown in Fig 6A. Data are represented as mean ± SEM.
Figure EV6 MRP1 inhibitor MK‐571 shifts cellular thiol pools, further potentiating APR‐246 efficacy Total intracellular glutathione (GSH + GSSG) levels in six cell lines after 24‐h incubation +/− MK‐571 as determined by a glutathione reductase (GR) re‐cycling assay (n ≥ 3 for each cell line except HCT116 −/− where n = 2, n indicates individual experiments). Mean values for each cell line shown in Fig 6A. Data are represented as mean ± SEM.CC BY · PubMed Central
Figure 7 GSH and Cys availability determines APR‐246/MQ accumulation and sensitivity to APR‐246 14C accumulation (cpm/mg/ml) in HCT116 WT and R248W mutant TP53 cells transfected with MRP1 or xCT siRNAs following 24 h of 14C ‐APR‐246 treatment +/− MK‐571. Indicated values are mean values from four MRP1 siRNAs (n ≥ 3), three xCT siRNAs (n = 1–2) and two control siRNAs (n ≥ 3). Mean 14C accumulation after treatment and n of individual siRNAs is shown in Appendix Table S4. Data for control and MRP1 siRNAs after 14C ‐APR‐246 treatment is also shown in Fig 3D.Growth suppression in HCT116 WT and R248W cells transfected with MRP1 or xCT siRNAs after 48 h of APR‐246 treatment as shown by WST‐1 assay. Indicated values are mean values of four MRP1 siRNAs (n ≥ 3), three xCT siRNAs (n = 1–2), and two control siRNAs (n ≥ 3). Data for control and MRP1 siRNA after APR‐246 single treatment are also included in Fig 1I. Values and n for individual siRNAs shown in Appendix Fig S7C.Total intracellular glutathione (GSH + GSSG per 106 cells) in HCT116 WT cells as shown by GR re‐cycling assay 48 h post‐transfection of siRNA. Indicated values are means from four MRP1 siRNAs (n = 3), two xCT siRNA (n = 2–3), and two control siRNAs (n = 2–3). Values and n for individual siRNAs shown in Appendix Fig S7K.Total intracellular glutathione (GSH + GSSG per 106 cells) in HCT116 WT and R248W cells measured by GR re‐cycling assay after 24 h of MK‐571 or sulfasalazine (SSZ) treatment (n ≥ 3, except SSZ where n = 2, n indicated by dots). 14C accumulation (cpm/mg/ml) in HCT116 WT and R248W cells at 24‐h treatment with 14C ‐APR‐246, combined with MK‐571 or sulfasalazine (SSZ), (n ≥ 4, except SSZ where n = 2, n indicated by dots). Data for 14C ‐APR‐246 +/− MK‐571 is also shown in Fig 3C and Appendix Fig S3D.Protein concentration of HCT116 WT and R248W assessed by DC™ Protein assay at 24 h treatment with APR‐246 +/− MK‐571 or sulfasalazine (SSZ), or untreated (n ≥ 4, except SSZ where n = 2, n indicated by dots).OVCAR‐3 (R248Q) confluence by IncuCyte® during 72‐h treatment with APR‐246 +/− MK‐571 or sulfasalazine (SSZ) (n = 3). Part of the data are shown in Fig 1F.Growth suppression in OVCAR‐3 cells as determined by IncuCyte® during 72 h treatment with APR‐246 +/− MK‐571 or sulfasalazine (SSZ) depicted as heatmaps (n = 3). Data information: Data are represented as mean ± SEM. See also Appendix Fig S7 and Appendix Table S4.
Figure 7 GSH and Cys availability determines APR‐246/MQ accumulation and sensitivity to APR‐246 14C accumulation (cpm/mg/ml) in HCT116 WT and R248W mutant TP53 cells transfected with MRP1 or xCT siRNAs following 24 h of 14C ‐APR‐246 treatment +/− MK‐571. Indicated values are mean values from four MRP1 siRNAs (n ≥ 3), three xCT siRNAs (n = 1–2) and two control siRNAs (n ≥ 3). Mean 14C accumulation after treatment and n of individual siRNAs is shown in Appendix Table S4. Data for control and MRP1 siRNAs after 14C ‐APR‐246 treatment is also shown in Fig 3D.Growth suppression in HCT116 WT and R248W cells transfected with MRP1 or xCT siRNAs after 48 h of APR‐246 treatment as shown by WST‐1 assay. Indicated values are mean values of four MRP1 siRNAs (n ≥ 3), three xCT siRNAs (n = 1–2), and two control siRNAs (n ≥ 3). Data for control and MRP1 siRNA after APR‐246 single treatment are also included in Fig 1I. Values and n for individual siRNAs shown in Appendix Fig S7C.Total intracellular glutathione (GSH + GSSG per 106 cells) in HCT116 WT cells as shown by GR re‐cycling assay 48 h post‐transfection of siRNA. Indicated values are means from four MRP1 siRNAs (n = 3), two xCT siRNA (n = 2–3), and two control siRNAs (n = 2–3). Values and n for individual siRNAs shown in Appendix Fig S7K.Total intracellular glutathione (GSH + GSSG per 106 cells) in HCT116 WT and R248W cells measured by GR re‐cycling assay after 24 h of MK‐571 or sulfasalazine (SSZ) treatment (n ≥ 3, except SSZ where n = 2, n indicated by dots). 14C accumulation (cpm/mg/ml) in HCT116 WT and R248W cells at 24‐h treatment with 14C ‐APR‐246, combined with MK‐571 or sulfasalazine (SSZ), (n ≥ 4, except SSZ where n = 2, n indicated by dots). Data for 14C ‐APR‐246 +/− MK‐571 is also shown in Fig 3C and Appendix Fig S3D.Protein concentration of HCT116 WT and R248W assessed by DC™ Protein assay at 24 h treatment with APR‐246 +/− MK‐571 or sulfasalazine (SSZ), or untreated (n ≥ 4, except SSZ where n = 2, n indicated by dots).OVCAR‐3 (R248Q) confluence by IncuCyte® during 72‐h treatment with APR‐246 +/− MK‐571 or sulfasalazine (SSZ) (n = 3). Part of the data are shown in Fig 1F.Growth suppression in OVCAR‐3 cells as determined by IncuCyte® during 72 h treatment with APR‐246 +/− MK‐571 or sulfasalazine (SSZ) depicted as heatmaps (n = 3). Data information: Data are represented as mean ± SEM. See also Appendix Fig S7 and Appendix Table S4.CC BY · PubMed Central
Figure 8 Thiol‐bound MQ provides a drug reservoir that increases availability of MQ for targeting mutant p53 MQ can bind both high molecular weight (HMW) targets such as mutant p53 and low molecular weight (LMW) targets, e.g., GSH and Cysteine. MQ conjugation to GSH (GS‐MQ) is reversible, indicating that MQ can transfer between multiple HMW and LMW cellular targets. Thus, GS‐MQ serves as an intracellular drug reservoir. MRP1 regulates GSH and oxidized GSH (GSSG) content and exports GS‐MQ. Therefore, MRP1 inhibition potentiates the effect of APR‐246/MQ through a dual mechanism: (1) inhibition of GS‐MQ efflux and (2) disruption of the intracellular thiol balance sensitizing cells to oxidative stress. We postulate that an MQ reservoir is similarly formed by conjugation to other thiol (R‐SH) targets, e.g., Cys. Furthermore, xCT and MRP1 collectively regulate LMW target availability and thus the intracellular reservoir of MQ, thereby governing sensitivity to APR‐246.
Figure 8 Thiol‐bound MQ provides a drug reservoir that increases availability of MQ for targeting mutant p53 MQ can bind both high molecular weight (HMW) targets such as mutant p53 and low molecular weight (LMW) targets, e.g., GSH and Cysteine. MQ conjugation to GSH (GS‐MQ) is reversible, indicating that MQ can transfer between multiple HMW and LMW cellular targets. Thus, GS‐MQ serves as an intracellular drug reservoir. MRP1 regulates GSH and oxidized GSH (GSSG) content and exports GS‐MQ. Therefore, MRP1 inhibition potentiates the effect of APR‐246/MQ through a dual mechanism: (1) inhibition of GS‐MQ efflux and (2) disruption of the intracellular thiol balance sensitizing cells to oxidative stress. We postulate that an MQ reservoir is similarly formed by conjugation to other thiol (R‐SH) targets, e.g., Cys. Furthermore, xCT and MRP1 collectively regulate LMW target availability and thus the intracellular reservoir of MQ, thereby governing sensitivity to APR‐246.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Cited by

See all 42

Metadata

Authors
Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., Behrenbruch, C., Simpson, K. J., Hollande, F., Abrahmsen, L., Clemons, N. J., & Wiman, K. G.
Affiliations
  • Karolinska Institutet (SE)
  • Peter MacCallum Cancer Centre (AU)
  • The University of Melbourne (AU)
  • University of Cambridge (GB)
Corresponding author
Wiman, Klas G
Venue
EMBO Molecular Medicine
Published
2020-12-14
Volume
13
Issue
2
Pages
e10852-e10852
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3110888894
Cited by
41
References
80
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 7 · 2022: 11 · 2021: 6 · 2020: 2
FWCI
2.35
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Vetenskapsrådet (2017‐01509)
  • Cancerfonden (18 0774)
  • Barncancerfonden (PR2017‐0106)
  • Radiumhemmets Forskningsfonder (171213)
  • Knut och Alice Wallenbergs Stiftelse
  • Aprea Therapeutics
  • Karolinska Institutet
  • Department of Health, Australian Government | National Health and Medical Research Council (APP1120293, GNT1164081)
  • Department of Health and Human Services, State Government of Victoria (MCRF16002)
  • Tour de Cure Foundation (RSP ‐ 0004 ‐ 17/18)
  • UKRI | Medical Research Council (RG84369)
  • Australian Cancer Research Foundation
  • Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program
  • Peter MacCallum Cancer Centre Foundation
  • University of Melbourne Research Collaborative Infrastructure Program
  • Cancer Research UK (RG81771/84119)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
APR-246, PRIMA-1MET, mutant p53, TP53 mutation, glutathione conjugation, redox homeostasis, cancer cell death, myelodysplastic syndrome
MeSH terms
Pharmaceutical Preparations, Humans, Mutation, Neoplasms, Quinuclidines, Sulfhydryl Compounds, Tumor Suppressor Protein p53, Cell Death, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. https://app.cochat.ai/papers/10.15252/emmm.201910852
The paper
Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., Behrenbruch, C., Simpson, K. J., Hollande, F., Abrahmsen, L., Clemons, N. J., & Wiman, K. G. (2021). A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201910852

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.